India Pharma Outlook Team | Tuesday, 29 July 2025
Torrent Pharmaceuticals is preparing to launch semaglutide, both oral and injectable, once the patent for the drug expires in early 2026.
This positions Torrent as one of the initial entries in the race for India's pharmaceutical players to get into the important and growing global diabetes and weight management market space. At the moment, semaglutide is a monopoly product by originator companies.
The good news is that semaglutide is a blockbuster drug for type 2 diabetes and obesity and expects to lose its primary patent in India, Canada, and Brazil by March 2026. Torrent is preparing to make a fast launch to capitalize on the expected surge and intends to enter this market as soon as possible. Torrent has already started late-stage development and is rumored to be creating partnerships for manufacturing and distribution.
Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment
The Indian pharmaceutical marketplace is booming as a number of domestic companies are positioned to take advantage of the patent cliff of semaglutide. Torrent is differentiated by its intended approach to launch both formulations pills and injections concurrently, quickly establishing large market share.
Positioning itself as a high-value specialty generic producer. As global demand for anti-obesity and diabetes drugs surges, Indian manufacturers like Torrent are positioning themselves not just for domestic distribution but for exports to emerging markets where access to such therapies remains limited.
With semaglutide’s market potential climbing rapidly, Torrent’s timely investment signals confidence in riding the next big growth wave in global pharma.
